Display options
Share it on

Pediatr Nephrol. 2021 Oct;36(10):3211-3219. doi: 10.1007/s00467-021-05045-4. Epub 2021 Apr 21.

Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.

Pediatric nephrology (Berlin, Germany)

Charlotte E Bryant, Azita Rajai, Nicholas J A Webb, Ronald J Hogg

Affiliations

  1. Research and Innovation, Manchester University NHS Foundation Trust, Nowgen Building, Grafton St., Manchester, M13 9WU, UK. [email protected].
  2. Research and Innovation, Manchester University NHS Foundation Trust, Nowgen Building, Grafton St., Manchester, M13 9WU, UK.
  3. Centre for Biostatistics, Division of Population Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  4. , Kailua Kona, Hawaii, USA.

PMID: 33881639 PMCID: PMC8445872 DOI: 10.1007/s00467-021-05045-4

Abstract

BACKGROUND: Studies have shown that losartan reduces serum uric acid in adults, unlike angiotensin-converting enzyme inhibitors. A previous study demonstrated that losartan and enalapril had comparable effects on proteinuria in children.

METHODS: We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared. We have now evaluated (a) the effects of these medications on SUA in 248 children with proteinuria and (b) the correlation between changes in SUA and eGFR.

RESULTS: SUA levels after 36 months were found to be increased when compared to baseline in both losartan and enalapril groups. The mean change in SUA from baseline was significantly different at 12 months between 23 hypertensive patients randomised to losartan (3.69% decrease [95% CI 11.31%, 3.93%]) and 24 randomised to enalapril (12.57% increase [95% CI 3.72%, 21.41%]), p = 0.007. This significant difference remained after 24, 30 and 36 months but was observed in the entire group of 248 patients only at 12 months. There was a statistically significant negative correlation between changes in SUA and changes in eGFR at each time point over 36 months.

CONCLUSIONS: Losartan may have long-term beneficial effects on SUA and eGFR in children with proteinuria.

© 2021. The Author(s).

Keywords: Children; Chronic kidney disease (CKD); Hypertension; Hyperuricemia; Proteinuria

References

  1. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S69-73 - PubMed
  2. Am J Kidney Dis. 2006 Jan;47(1):51-9 - PubMed
  3. N Engl J Med. 2008 Oct 23;359(17):1811-21 - PubMed
  4. Lancet. 1997 Jun 28;349(9069):1857-63 - PubMed
  5. Pediatr Nephrol. 2014 Jun;29(6):999-1008 - PubMed
  6. Am J Physiol Renal Physiol. 2008 Oct;295(4):F1134-41 - PubMed
  7. Pharmacogenomics. 2015 Jul;16(8):855-63 - PubMed
  8. Int J Clin Pharmacol Ther. 2020 Jan;58(1):21-28 - PubMed
  9. J Pediatr. 2003 Jul;143(1):89-97 - PubMed
  10. N Engl J Med. 2020 Jun 25;382(26):2504-2513 - PubMed
  11. Kidney Int. 1999 Nov;56(5):1879-85 - PubMed
  12. Am J Kidney Dis. 2018 Dec;72(6):798-810 - PubMed
  13. Kidney Int. 2012 Oct;82(7):819-26 - PubMed
  14. J Am Soc Nephrol. 2012 Jan;23(1):165-73 - PubMed
  15. J Hum Hypertens. 2006 Jan;20(1):45-50 - PubMed
  16. J Am Soc Nephrol. 2007 Jun;18(6):1889-98 - PubMed
  17. Am J Kidney Dis. 2006 Aug;48(2):221-30 - PubMed
  18. Hypertension. 2011 Jul;58(1):2-7 - PubMed
  19. Clin Nephrol. 2013 Jul;80(1):40-6 - PubMed
  20. Nephrol Dial Transplant. 2018 Feb 1;33(2):231-241 - PubMed
  21. Am J Kidney Dis. 2018 Mar;71(3):362-370 - PubMed
  22. Int Urol Nephrol. 2019 Mar;51(3):467-473 - PubMed
  23. J Hypertens. 2010 Jun;28(6):1234-42 - PubMed
  24. Clin Exp Hypertens. 2015;37(3):192-6 - PubMed
  25. Am J Kidney Dis. 2015 Dec;66(6):984-92 - PubMed
  26. Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93 - PubMed
  27. Am J Kidney Dis. 2004 Oct;44(4):642-50 - PubMed
  28. Am J Hypertens. 2006 Feb;19(2):208-13 - PubMed
  29. J Am Soc Nephrol. 2007 Jun;18(6):1959-65 - PubMed
  30. Am J Nephrol. 2018;48(2):127-136 - PubMed
  31. J Pediatr. 2013 Jan;162(1):128-32 - PubMed
  32. Kidney Int. 2004 Aug;66(2):768-76 - PubMed
  33. Kidney Blood Press Res. 2012;35(3):153-60 - PubMed
  34. Clin Exp Nephrol. 2019 Mar;23(3):362-370 - PubMed
  35. N Engl J Med. 2001 Sep 20;345(12):861-9 - PubMed
  36. Am J Kidney Dis. 2010 Aug;56(2):264-72 - PubMed
  37. Nephrol Dial Transplant. 2016 Sep;31(9):1471-7 - PubMed
  38. J Am Soc Nephrol. 2008 Jun;19(6):1204-11 - PubMed
  39. J Am Soc Nephrol. 2008 Dec;19(12):2407-13 - PubMed
  40. Ther Adv Cardiovasc Dis. 2017 Feb;11(2):57-62 - PubMed
  41. Intern Med. 2002 Oct;41(10):793-7 - PubMed
  42. Hypertens Res. 2012 Aug;35(8):867-73 - PubMed
  43. Am J Kidney Dis. 2009 May;53(5):796-803 - PubMed
  44. Am J Kidney Dis. 2018 Dec;72(6):776-778 - PubMed
  45. Clin J Am Soc Nephrol. 2010 Mar;5(3):417-24 - PubMed
  46. Pediatr Nephrol. 2018 Aug;33(8):1405-1409 - PubMed
  47. Am J Kidney Dis. 2015 Dec;66(6):945-50 - PubMed
  48. Nephrology (Carlton). 2017 Jun;22(6):441-448 - PubMed
  49. Nephron. 2001 Apr;87(4):333-9 - PubMed
  50. Am J Nephrol. 2011;33(4):352-7 - PubMed
  51. Ren Fail. 2018 Nov;40(1):289-297 - PubMed
  52. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7 - PubMed
  53. J Am Soc Nephrol. 2018 Aug;29(8):2225-2233 - PubMed

Publication Types